Pharma firm Suven Life Sciences today said the European Patent Office (EPO) has issued patent to one of its compound which is used in treating disorders like Alzheimer's, Parkinson and Schizophrenia.
The company secures product patent for one of its new chemical entity (NCE) which is used for the treatment of disorders associated with neurodegenerative diseases, valid until 2025, Suven said in a statement.
The granted claims of the patent include the class of selective compounds discovered by Suven and are useful in the treatment related to neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia, it said.
With this new patent, Suven has a total of eight granted European product patents for their NCEs in central nervous system therapy.
All the eight EPO patents have been validated in the 37 member countries of Europe, including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.
Shares of Suven Lifesciences were trading at Rs 33.80 on BSE, up 3.68 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app